Drug Name: Epkinly
Indications: To treat relapsed or refractory diffuse large B-cell lymphoma (not otherwise specified) and high-grade B-cell lymphoma after two or more lines of systemic therapy.
Active Ingredient: Epcoritamab-bysp
Company: Genmab A/S
Approval Date: 5/19/2023
More Details: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761324s000lbl.pdf